Correction to: A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency (Journal of Clinical Immunology, (2025), 45, 1, (158), 10.1007/s10875-025-01952-5)

The caption to Figure 1 contained an error in the description of dosing for treatment-experienced patients. The caption incorrectly states that period 1 of dosing was daily when in fact it was weekly. The corrected caption should read: Fig. 1 Study schema for treatment-experienced patients. The lighter blue boxes indicate period 1 – weekly dosing – and the darker blue boxes indicate period 2 – biweekly dosing. IGSC = subcutaneous immunoglobulin; early term = early termination; W0 = week 0; QOL = quality of life; PK = pharmacokinetic. Figure 2 contained an error in the depiction of the timing of IgG trough levels. The third box indicating the third sample was labeled “W4”. It should have been labeled “W1” for Week 1. The corrected figure should read: The title to Table 2 contained an error. The title reads: “Pharmacokinetic parameters following weekly and biweekly dosing of 1GSC 20% in treatment-experienced patients.” The name of the administered product should be “IGSC 20%” not “1GSC 20%”. The corrected title should read: “Pharmacokinetic parameters following weekly and biweekly dosing of IGSC 20% in treatment-experienced patients.” The original version has been corrected.